About

Steven C. Gilman, Ph.D. served as a Class I director of Akebia Therapeutics' Board of Directors and resigned from the Board effective April 1, 2026. His resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. During 2025 and into 2026 through the date of his resignation, Dr. Gilman served on the Company's Compensation Committee and its Research & Development Committee.

Roles

Akebia Therapeutics, Inc.
Director (Class I) (resigned effective April 1, 2026) · Current role
Present

Director Compensation

FY 2025
Fees earned or paid in cash
$62,500
Stock awards
$139,944
Option awards
$182,582
Total
$385,026

Also at Akebia Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.